英文互译镜像站

CA-170

Last updated

CA-170
CA-170.svg
Identifiers
  • (2S,3R)-2-[[(1S)-3-amino-1-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-3-oxopropyl]carbamoylamino]-3-hydroxybutanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C12H20N6O7
Molar mass 360.327 g·mol−1
3D model (JSmol)
  • C[C@H]([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NC(=NO1)[C@H](CO)N)O
  • InChI=1S/C12H20N6O7/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-17-9(18-25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4-,5+,6+,8+/m1/s1
  • Key:HFOBENSCBRZVSP-LKXGYXEUSA-N

CA-170 is an investigational new drug being evaluated as an immune checkpoint inhibitor for the treatment of cancer. Developed by Aurigene Oncology, it is an orally available small molecule designed to selectively inhibit the immune checkpoint proteins PD-L1 [1] and VISTA, [2] both of which are key negative regulators of T-cell activation implicated in cancer immune evasion. [3] [4]

By targeting these immune pathways, CA-170 aims to restore and enhance the immune system's ability to recognize and eliminate tumor cells, offering the potential for improved anti-tumor responses across a variety of cancers. [4] [5]

References

  1. ↑ Sasikumar PG, Ramachandra M (2022). "Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development". Frontiers in Immunology. 13 752065. doi: 10.3389/fimmu.2022.752065 . PMC   9108255 . PMID   35585982.
  2. ↑ Wu C, Cao X, Zhang X (October 2021). "VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses". RSC Medicinal Chemistry. 12 (10): 1672–1679. doi:10.1039/d1md00185j. PMC   8528208 . PMID   34778768.
  3. ↑ "CA‑170". Curis, Inc. Retrieved 2025-06-22.
  4. 1 2 Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, et al. (June 2021). "PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy". Communications Biology. 4 (1) 699. doi:10.1038/s42003-021-02191-1. PMC   8187357 . PMID   34103659.
  5. ↑ Lee JJ, Powderly JD, Patel MR, Brody J, Hamilton EP, Infante JR, et al. (2017). "Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas". Journal of Clinical Oncology. 35 (15 suppl) TPS3099. doi:10.1200/JCO.2017.35.15_suppl.TPS3099.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
蚪侠镜像站群 霸屏SEO镜像站群 蚂蚁镜像站群 主动推送镜像站群 YES镜站站群引擎